[Disclosure] Alteogen (196170) Postpones Expected Date of Acquiring Altos Biologics Shares to Dec 31 Due to Schedule Adjustments in Subsidiary Merger

Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2024-11-14

Disclosure Type: Decision on Acquisition of Shares and Investment Securities of Another Corporation (Amendment)

💡 3-Second Summary

Alteogen has postponed the expected date of acquiring new merger shares of its subsidiary, Altos Biologics, from December 24 to December 31, 2024, following schedule revisions in the integration process between its subsidiaries.

📊 1. [Key Disclosure Content & Major Figures Summary]

• Amendments (Timeline Postponement):
  • Expected Date of Acquisition: Delayed from December 24, 2024 $\rightarrow$ To December 31, 2024
  • Board Resolution Date: Adjusted from November 7, 2024 $\rightarrow$ To November 14, 2024
• Issuing Company (Target Entity): Altos Biologics, Inc. (A subsidiary of Alteogen; Par capitalized at approx. KRW 3.78B)
• Acquisition & Ownership Metrics:
  • Number of Shares to Acquire: 859,018 Common Shares (New Share Issuance)
  • Acquisition Amount: KRW 31,165,173,040 (Approx. KRW 31.2B)
  • Weight Against Parent Equity Base: 21.08% of Alteogen’s equity
  • Post-Acquisition Shareholding Position: 5,859,018 shares / 63.46% stake
• Method & Purpose: Acquired via new share issuance resulting from an absorption merger where the surviving subsidiary (Altos Biologics) absorbs the dissolving subsidiary (Alteogen Healthcare) to enhance operational efficiency through corporate streamlining.
• Financial Cash Burden: As this transaction represents an exchange of equity and new share distribution driven by an internal subsidiary merger, there is zero additional cash outflow or capital contribution required from Alteogen; it will only involve an accounting aggregation of subsidiary investment values.

📈 2. [Expert View: What This Disclosure Means for Investors]

• Minor Fine-Tuning of Corporate Restructuring Timeline: An adjustment in the execution schedule and board resolution timelines made one week after the initial announcement pushed the final share acquisition date to the final day of the fiscal year (December 31). This adjustment represents a standard minor administrative shift rather than any structural alteration in management’s core strategic goals or integration blueprints.
• Accounting Rebalancing Without Cash Outflow: While the transaction size is valued at approximately KRW 31.2 billion, it does not involve any actual cash drain or external paid-in capital expansion from Alteogen. Because the dissolved unit’s internal equity is simply converted into the surviving entity’s new shares, there are no liquidity risks or cash flow constraints despite the significant nominal acquisition size (21.08% of equity).
• Investor Caution: This filing serves as an amendment notification outlining changes to the timeline of a major investment transaction that accounts for 12.17% of consolidated assets. Investors should cross-reference this timeline with the ongoing progress and upcoming general shareholder approvals of the underlying subsidiary merger to map out the definitive closing window.

📝 Editor’s Comment (by K-STOCK Editor)

Alteogen’s internal restructuring schedule, involving the merger between Altos Biologics and Alteogen Healthcare, has been shifted slightly by one week, anchoring the final share acquisition to the last day of the year, December 31. While a standard disclosure over KRW 30B in asset acquisition typically triggers dilution or cash flow liquidity concerns, this adjustment remains a non-cash accounting aggregation driven by an internal stock swap. Since this represents a minor routine timeline calibration, it carries no immediate pressure on trading metrics, and long-term participants should simply observe whether the consolidated governance structures tie up smoothly at the close of H2.

📢 Disclaimer & Source Information

Source: This content was structured and newly written based on the official submitted data from the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.